Ewing Sarcoma Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Oncternal Therapeutics, Salarius Pharma, Eisai, Gradalis

Delveinsight Business Research LLP
As per DelveInsight, the Ewing Sarcoma Market is expected to change owing to the improvement in the diagnosis, incremental healthcare expenditure across the world, and the expected launch of emerging therapies during the forecast period.

Companies all over the globe are persistently working towards developing new treatment therapies, and some of the key players at the global level are Tyme, Gradalis, Oncurious, Eisai, and others.

DelveInsight’s “Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ewing Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Ewing Sarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ewing Sarcoma: An Overview

Ewing’s sarcoma, also known as a peripheral primitive neuroectodermal tumor, Askin tumor, extra-osseous Ewing sarcoma, and Ewing sarcoma family of tumors, is a malignant tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing’s sarcoma can develop in any bone, it usually affects the long bones, like the femur, tibia, humerus, and the bones of the pelvis. Occasionally, this tumor begins in the muscles and soft tissues (known as extra-osseous Ewing’s sarcoma).

The cause of Ewing’s sarcoma is unknown, except that the genetic material in chromosome number 11 and 22 is mismatched. There is usually pain and possibly swelling at the site of the tumor. However, the tumor may be present for many months before it becomes large enough to cause pain and swelling. In some cases, the first symptom of Ewing’s sarcoma is the presence of a mass.

Ewing Sarcoma Market Key Facts

The incident cases of Ewing Sarcoma recorded in the United States are around 200 -250, while in the case of Europe, the number of diagnosed patients each year is 600.

The lowest incident population of Ewing sarcoma was recorded in Japan, compared to the US and EU5.

Among the 7MM, EU5 has a significant number of Ewing’s sarcoma, as the estimated incidence is considered to be 1.5 per million among people of European descent.

According to the National Organization for Rare Disorders, the annual incidence of Ewing Sarcoma is 3 children per million. Almost 200–250 children and youngsters in the US are diagnosed with Ewing tumors yearly. Two-thirds will be long-term survivors (more than five years).

According to a study by Khan et al. (2021), Ewing’s sarcoma most commonly occurs between 15 and 20 years of age, and reportedly, Around 80% of cases are found in patients under 18 years of age, and less than 1% of cases are found in adults greater than 40 years of age.

Ewing Sarcoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Ewing Sarcoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Ewing Sarcoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ewing Sarcoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Ewing Sarcoma Epidemiology, Segmented as –

Incident Cases of Ewing Sarcoma in the 7MM [2019–2032]

Age-Specific Cases of Ewing Sarcoma [2019–2032]

Treatable Cases of Ewing Sarcoma [2019–2032]

Subtype-specific Cases of Ewing Sarcoma [2019–2032]

Gender-Specific Cases of Ewing Sarcoma [2019–2032]

Ewing Sarcoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Ewing Sarcoma market or expected to be launched during the study period. The analysis covers the Ewing Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ewing Sarcoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Ewing Sarcoma Market Will Evolve and Grow by 2032 @ 


Ewing Sarcoma Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Ewing Sarcoma. Currently, Gradalis is leading the therapeutics market with its Ewing Sarcoma drug candidates in the most advanced stage of clinical development.

On April 10, 2023, Sumitomo Pharma Oncology, Inc., announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma.

The Leading Players in the Ewing Sarcoma Therapeutics Market Include:

Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals., Oncternal Therapeutics. Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and many others.

Ewing Sarcoma Emerging and Marketed Drugs Covered in the Report Include:

ONCT216: Oncternal Therapeutics

Seclidemstat: Salarius Pharmaceuticals

Eribulin mesylate: Eisai

Vigil EWS: Gradalis

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Ewing Sarcoma Competitive Intelligence Analysis

4. Ewing Sarcoma Market Overview at a Glance

5. Ewing Sarcoma Disease Background and Overview

6. Ewing Sarcoma Patient Journey

7. Ewing Sarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Ewing Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Ewing Sarcoma Unmet Needs

10. Key Endpoints of Ewing Sarcoma Treatment

11. Ewing Sarcoma Marketed Products

12. Ewing Sarcoma Emerging Drugs and Latest Therapeutic Advances

13. Ewing Sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Ewing Sarcoma Market Outlook (In US, EU5, and Japan)

16. Ewing Sarcoma Access and Reimbursement Overview

17. KOL Views on the Ewing Sarcoma Market

18. Ewing Sarcoma Market Drivers

19. Ewing Sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: